Sourcing Disclosure: Licensed Bangladesh Global Sourcing Specialist facilitating global access under Named Patient Regulations.
Expert-reviewed clinical data for prescription-only medicine.


Capivast (Capivasertib) 200 mg Tablets | Advanced Breast Cancer Therapy in AKT Mutation
- Used for: Adult patients with HR-positive, HER2-negative advanced breast cancer harboring PIK3CA/AKT1/PTEN alterations.
- Availability: In Stock
- Shipping: Express Global Shipping (7-14 days depending on region).
- Requirement: Valid prescription from a licensed healthcare provider required.
✓ WHO GMP Certified
✓ Reviewed By Medical Expert
✓ Batch Examined in Lab
Need Patient Access Support?
Our team provides verified global sourcing assistance to help you navigate international shipping and prescription requirements safely.
Capivast, contains the active ingredient Capivasertib in a 200 mg tablet, is a first-in-class oral AKT inhibitor. It is the generic equivalent of the innovator medication, Truqap. Unlike general chemotherapy, Capivasertib specifically targets a pathway that has become overactive due to genetic mutations. By “switching off” the signals that tell cancer cells to multiply and survive, Capivast helps control tumor growth and improve outcomes for patients whose cancer has progressed on standard hormone therapies. Based on clinical protocols from the FDA, EMA, and NCCN, Capivasertib is indicated for: In many breast cancers, a protein called AKT acts like an “engine” that drives the cell to grow, divide, and resist dying. Genetic mutations (PIK3CA, AKT1, or PTEN) can keep this engine running permanently. Capivasertib is a potent inhibitor that binds to all three forms of the AKT protein (AKT1, 2, and 3). By blocking this central node in the signaling network, the medication effectively cuts the power to the cancer cell’s growth signals. When used in combination with Fulvestrant, it provides a dual attack: one blocking the AKT engine and the other downregulating the estrogen receptors that fuel the tumor. The dosing of Capivasertib follows a specific “intermittent” schedule to help your body manage the treatment. Clinical safety data from the CAPItello-291 trial (published on ClinicalTrials.gov and the official FDA label) highlight the following key areas for monitoring: Critical Risk: Hyperglycemia (High Blood Sugar) Because the AKT pathway also helps regulate how your body uses sugar, blocking it can cause blood sugar to rise. Critical Risk: Diarrhea Diarrhea is very common, affecting over 70% of patients in clinical trials. Common Adverse Reactions: Lab Changes: Decreased hemoglobin (anemia) or decreased white blood cells (lymphocytes). Grapefruit: Strictly avoid grapefruit and grapefruit juice, as they can interfere with how your liver breaks down the drug, leading to dangerous toxicity. Capivast does not require cold chain storage. Store the tablets at controlled room temperature (20C° to 25C°) in a dry place. Keep them in their original packaging to protect them from light and moisture. In targeted oncology, the precision of the tablet formulation is critical for consistent absorption. Capivast is manufactured by Everest Pharmaceuticals Ltd. in a specialized facility that adheres to WHO GMP (World Health Organization Good Manufacturing Practices) standards. This ensures that every 200 mg tablet undergoes rigorous bioequivalence and stability testing, providing a high-quality, clinically effective generic version that matches the safety and efficacy profile of the innovator brand, Truqap. If Capivast is not available in your local pharmacy, international healthcare frameworks often allow for the legal importation of life-saving medicines for personal use. Verification: Always consult with your local customs or drug administration authority to ensure you comply with the specific import documentation needed for your region. The “4 days on, 3 days off” schedule is a deliberate clinical design. It allows your body—specifically your blood sugar levels and digestive system—a rest period to recover, making the long-term treatment more tolerable while still effectively suppressing the cancer cells. If it has been less than 4 hours from your scheduled time, take it immediately. If more than 4 hours have passed, skip the missed dose and wait for your next scheduled time. Never take two doses at once to “make up” for a missed one. Yes, but it requires very close coordination between your oncologist and your primary doctor. Since Capivasertib can raise blood sugar, your diabetes medications may need to be adjusted during treatment.Clinical Data & Patient Guide
What exactly is this medication for?
How does Capivasertib work to fight cancer?
How is Capivast administered?
What side effects and safety data should I watch for?
Are there special precautions for certain populations?
How should I store Capivast?
Manufacturer Quality & Assurance
Global Access to Medication
Frequently Asked Questions (FAQ)
Why do I only take the medicine for 4 days a week?
What should I do if I miss a dose?
Can I take this medicine if I have diabetes?




